Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Dioxoles
  • Neoplasms
  • Tetrahydroisoquinolines

abstract

  • The MTD levels of trabectedin given weekly for 3 weeks every 4 weeks is 0.61 mg/m(2) as a 1-hour infusion and 0.58 mg/m(2) as a 3-hour infusion. The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules.

publication date

  • May 15, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-2889

PubMed ID

  • 19417019

Additional Document Info

start page

  • 3591

end page

  • 9

volume

  • 15

number

  • 10